TRITON TIMI 38 AHA 2007.pptVIP

* * * * * * * * * * * * * * * * * * * * * * PRINCIPLE – TIMI 44 TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel TRITON-TIMI 38AHA 2007Orlando, Florida Disclosure Statement:  The TRITON-TIMI 38 trial was supported by a research grant to the Brigham and Women’s Hospital from Daiichi Sankyo Co. Ltd and Eli Lilly Co. Antiplatelet Therapy for PCI Dual antiplatelet Rx (ASA + thienopyridine) is standard of care: Ticlopidine Clopidogrel Clinical need to improve on benefits observed with clopidogrel Prasugrel Novel thienopyridine Eff